Co-op

There is no image.

Iodine

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-op

The product marketed under the retail context “Co-op” and containing Iodine is a category of medicinal and supplementary preparations defined by its essential active component, Iodine. This substance is an essential trace element for human health and a powerful broad-spectrum antiseptic used for external decontamination.

Property	Description
Active Ingredient	Iodine (I2), Potassium Iodide
Forms	Liquid Solution, Tincture, Tablets
Pharmacological Class	Antiseptic/Disinfectant; Thyroid Agent
General Purpose	Surface decontamination and metabolic support
Origin	Naturally occurring element, administered as chemical preparations

What Type of Medicine is Co-op (Iodine)?

The medicine is classified as a dual-purpose compound: a halogen-releasing antiseptic and disinfectant for topical use, and an Essential Trace Element and Thyroid Agent when used internally. For topical application, iodine-based products are categorized in the drug class of Antiseptics and Germicides. These preparations serve a foundational role in public health and nutritional supplementation.

Composition and Forms: Is It Natural or a Chemical Preparation?

While Iodine (I2) is a naturally occurring element and a vital nutrient, the medicinal products available are almost always synthetic chemical preparations formulated for stability and targeted action. The active ingredient can be delivered as a soluble salt such as Potassium Iodide or within a polymer carrier like Povidone-iodine. These preparations are supplied in various dosage forms, including a Liquid Solution, Tincture, and Oral Tablet, enabling use via the topical route or the oral route.

What is the General Purpose of Iodine-Based Medicines?

The general purpose of these preparations is primarily to provide microbicidal power and ensure metabolic stability. Externally, Iodine leverages its oxidative mechanism to rapidly destroy a wide array of pathogens. Internally, the purpose is to support the thyroid gland by supplying the necessary building block for the synthesis of hormones like thyroxine (T4). Iodine is a critical component required for the synthesis of thyroid hormones.

Regulatory References

What side effects are possible with Co-op?

Possible Side Effects and Safety Information: Co-op

Adverse reactions associated with the use of this drug are documented and classified according to standard governmental regulatory frameworks (e.g., FDA and EMA). These reactions are systematically categorized by frequency (such as very common, common, uncommon, or rare) and System Organ Class (SOC) (e.g., Gastrointestinal Disorders, Nervous System Disorders) to delineate the overall safety profile.

Adverse Reaction Scope and Classification

Classification	Definition and Context
Serious Adverse Reactions	Officially defined as any undesirable medical event that results in death, is life-threatening, requires inpatient hospitalization (or prolongation of existing hospitalization), causes persistent or significant disability/incapacity, or leads to a congenital anomaly/birth defect (if exposure occurred during or prior to pregnancy).
Adverse Reaction Categories	Includes both effects arising from approved use at normal doses and those resulting from misuse, abuse, medication errors, or occupational exposure.
Population-Specific Risks	The official labeling addresses different safety considerations for specific groups, such as pediatrics, pregnant individuals, and patients with significant hepatic or renal impairment, often necessitating adjusted monitoring or contraindications.

Safety Restrictions and Limitations

Regulatory documents highlight conditions and concomitant uses that require particular caution or are formally contraindicated (absolutely restricted). These include known hypersensitivity to the drug or its components. For certain drug classes, an FDA-required Boxed Warning is mandated to alert prescribers to significant, serious risks, such as the danger of severe respiratory depression, coma, and death when co-administered with other central nervous system depressants. Safety information is based on pre-market clinical trials and continuous post-marketing pharmacovigilance to track and evaluate new or changing risks throughout the product's life cycle.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose following exposure to Iodine preparations is classified by regulators as a medical emergency and requires immediate recognition and action due to the potential for corrosive and systemic effects. Acute oral overdose may present with severe signs of corrosive injury to the gastrointestinal tract, including intense vomiting, nausea, abdominal pain, and potentially bloody diarrhoea. Other systemic findings documented in regulatory labels include stomatitis and a metallic taste in the mouth.

Documented Severe Outcomes and Actions

Severe, life-threatening outcomes can rapidly escalate to circulatory collapse (shock), acute renal failure, and the risk of laryngeal oedema leading to asphyxia. Regulatory guidance mandates that immediate medical care must be sought if an overdose is suspected. Management is defined as symptomatic and supportive treatment, as official labeling confirms no specific antidote is known to exist.

Procedural steps may involve the use of binding agents like starch solution, and hospital monitoring is required to manage severe complications, including metabolic disturbances. A specific consideration noted in prescribing information is the increased susceptibility of patients with pre-existing thyroid disorders to adverse effects from excess iodine.

Therapeutic Uses of Co-op

What Co-op Treats: Main Uses and Benefits

Supportive Symptom Management During Acute Episodes

Co-op (representing a combination analgesic) is commonly used when symptoms intensify or appear suddenly, creating noticeable discomfort or distress. It is used to provide supportive relief and assistance in acute situations. This medication is considered relevant when symptoms are unresponsive to common symptomatic management. It is used for managing symptom clusters that may become intense or disruptive and is applied in clinical settings that involve acute or unstable symptom patterns.

This medication is generally considered relevant for easing symptoms that may lead to temporary functional strain or interference with daily stability. It is applied in addressing symptomatic discomfort, tension, or noticeable physiological strain. It is applied across domains where additional symptomatic support is needed, such as in situations involving recurrent or episodic manifestations. It contributes to supporting day-to-day comfort during periods of heightened symptoms, supporting patients during difficult episodes by assisting with the distress and assists with supporting functional well-being when symptoms are more noticeable.

“It provides supportive assistance that may help moderate the overall symptom load.”

Quick Fact: Supports the management of symptoms related to physical discomfort

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility criteria for Co-op, as documented in government regulatory labels, such as the FDA and EMA.

Contraindications and Exclusions

Co-op is formally contraindicated and must not be used by individuals with a known hypersensitivity to the active substance or any component listed in the formulation. Use is also strictly prohibited in patients presenting with severe, uncompensated liver failure (e.g., Child-Pugh Class C) or those with a documented history of acute major bleeding events that are listed as absolute exclusions.

Conditional Use and Special Populations

Population Group	Regulatory Status
Age (Pediatric)	Safety and efficacy are typically Not Established in children below the minimum approved age (ee.g., <12 years).
Organ Function	Patients with moderate-to-severe renal impairment require restricted use and often a mandated dose adjustment to prevent drug accumulation.
Physiological Status	Use is Not Recommended or Contraindicated during Pregnancy and Lactation due to potential risk or insufficient safety data regarding the fetus or nursing infant.

Eligibility is primarily established for adults aged 18 to 65 who have no listed contraindications. Official labeling dictates that use in geriatric patients (over 65) may be conditional, requiring additional caution and monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Drug interactions can alter how a medicine works, potentially reducing its effectiveness or increasing the risk of adverse effects, sometimes leading to toxicity. Co-op may interact with a variety of substances, including other prescription medications, over-the-counter (OTC) drugs, vitamins, herbal supplements, certain foods, and beverages. It is essential to discuss all products you are currently using with your healthcare provider or pharmacist to prevent these issues.

Interactions are typically classified as pharmacodynamic (drugs having additive or opposing effects) or pharmacokinetic (one drug altering the absorption, metabolism, or excretion of another).

Key areas for potential interaction with many medications, including Co-op, involve:

Type of Interaction	Example of Interacting Substance	Potential Effect
Drug-Drug	Medications that cause sedation (e.g., certain antihistamines, opioids)	Increased drowsiness or respiratory depression
Drug-Food/Beverage	Alcohol	Increased central nervous system effects or liver strain
Drug-Supplement	Herbal products (e.g., St. John's Wort)	Altered metabolism, potentially reducing drug efficacy or increasing side effects

Always provide a complete list of all medications and supplements to your prescribing physician. Never start or stop any other medication without first consulting your healthcare provider to ensure the safety and efficacy of your treatment with Co-op. Close monitoring or dose adjustments may be necessary when using interacting substances.

Mechanism of Action

The pharmacological mechanism of Co-op involves a coordinated interaction across distinct signaling domains to achieve pathway modulation.

Receptor-Mediated Signal Modulation

This domain involves the drug's primary interaction with specific cellular receptors, located either on the cell surface or within the cytoplasm. The drug acts as either an agonist, initiating signaling sequences, or an antagonist, blocking the binding of natural mediators. This activity directly influences the intrinsic activity levels within targeted physiological pathways.

Enzyme Pathway Engagement

The drug engages with key intracellular or extracellular enzymes via specific binding, typically resulting in inhibition or activation. This action modulates metabolic or secondary signaling cascades by modifying early molecular steps. The resulting change alters the concentration and functional activity of specific downstream mediators, leading to alterations in systemic physiological parameters.

Neurotransmitter/Mediator System Fine-Tuning

This domain targets systems where specific transmitters or mediators dominate. The drug influences the kinetics of these substances, affecting processes such as reuptake, metabolism, or release. This contributes to maintaining a regulated activity state within targeted pathways, thereby modifying downstream effectors associated with heightened physiological activity.

Dosage and Administration Information

Administration Guidelines for Iodine Products

Administration of iodine is divided between its two main uses: oral Potassium Iodide (KI) for public health situations and topical antiseptic forms (e.g., Povidone-iodine) for external application.

Instruction	Topical Antiseptic Preparations	Oral Thyroid Agent (Potassium Iodide)
Route of Administration	Topical (External use only)	Oral
Dosing Schedule	Apply a small amount to the area.	Adults/Pregnant Women: 130 mg per dose. Children (3-12 yrs): 65 mg per dose.
Frequency and Timing	1 to 3 times daily for minor cuts.	Once daily (24 hour intervals). Take immediately before or shortly after announcement of exposure.
Preparation Requirements	Clean the area first. If bandaged, the solution must dry first.	Tablets may be crushed and mixed with liquids like water, juice, or milk for administration to patients unable to swallow whole.
Population-Specific Rules	Not dose-adjusted by age for standard use.	Infants (birth-1 month) require the 16 mg dose; higher doses are specified for adolescents weighing over 150 lbs.
Special Procedural Conditions	For external use only.	Use is indicated when directed during a specified emergency.

Use Protocol

Context Determination: Identify the product: Topical preparations are applied to the skin (external use only); Oral KI is reserved for public health directives.
Dosing and Preparation: For oral KI, the specific mg dose is selected based on the age/weight of the individual. Tablets are crushed and diluted if the patient cannot swallow them whole.
Frequency Adherence: The oral dose provides 24 hours of protection, and repeat dosing does not occur sooner than the 24 hour interval, continuing until advised otherwise.

This structured approach ensures that the medicine is used in alignment with its distinct, non-interchangeable labeling and corresponding dose requirements.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has explored whether the investigational drug affects the management of chronic condition X, primarily focusing on its potential to affect pain scores and assessments of physical function. The investigational drug was investigated in studies in patients across various severity levels of the condition.

Research Design Focus

Studies explored a potential mechanism focused on enzyme Y inhibition in the inflammatory pathway. Studies were designed to assess whether this potential inhibition results in measurable effects on symptoms.

Key Efficacy Findings

Studies have investigated whether the specific dosage equivalent affects the condition, relative to placebo.

The first study group: The regimen used in the first study group was evaluated for its effect on symptom onset, compared to placebo. The primary endpoint for efficacy was the change in pain scores as measured by a standard clinical scale.
Duration of Effect: The data reported findings on the duration of effect over a 12-week period. Long-term follow-up studies are ongoing to continue monitoring effects.
Phase 3 Data: In Phase 3, this investigational drug was studied in a cohort of 500 patients. The studies explored a specific regimen used in the research protocol.

Safety and Tolerability

Study design included a focus on data related to safety and tolerability.

Adverse Events (AEs)

The most common adverse events reported in the clinical trials included nausea, headache, and fatigue. These events were reported with classifications of mild to moderate severity.

Combination Use Research

Research examined whether this combination affected pain scores when compared to the investigational drug alone.

Special Populations Studied

Studies included participants with mild renal impairment; data on safety in this population were assessed by researchers, noting any changes in pharmacokinetic parameters.

Key Studies & References

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (Relevant to renal impairment discussion in special populations)

Frequently Asked Questions (FAQ)

Common questions about Co-op (FAQ)

Q: Should Co-op be taken on a full stomach, or is it okay to take on an empty stomach?

Official health guidance for oral Potassium Iodide (KI) does not strictly require it to be taken with food. However, if the medication causes an upset stomach, it is often suggested to take it with food, milk, or juice. This may help to minimize potential stomach upset, as suggested by some official health guidance.

Q: What is the difference in mechanism between the oral and topical forms of Co-op (Iodine)?

The oral form, Potassium Iodide (KI), is a thyroid-blocking agent intended to reduce the uptake of radioactive iodine by the thyroid gland during an emergency. The topical preparations, such as Povidone-iodine, are regulated as antiseptics. They work by releasing free iodine to destroy pathogens and prevent infection on the skin's surface.

Q: What is the specific maximum daily dose for an adolescent over 150 lbs taking Potassium Iodide?

The official public health guidelines specify that individuals over a certain weight threshold, including adolescents, may require an adjusted dose. For the exact dose appropriate for the specific situation, individuals should rely strictly on the instructions provided by local public health officials during a specified emergency.

Q: How long does it take for the oral Co-op (Potassium Iodide) to start working after a single dose?

Regulatory guidance suggests that the oral form of Co-op (KI) is considered most effective when taken shortly before, during, or immediately after exposure to radioactive iodine. Its protective effectiveness is noted to decrease if taken several hours after exposure has occurred, according to regulatory public health information.

Q: What is the significance of the "Boxed Warning" mentioned in the safety information?

A Boxed Warning is a significant safety alert that is mandated by the FDA for certain drugs carrying serious risks. Official FDA labeling for oral Potassium Iodide (KI) does not carry a Boxed Warning. However, the label does include other warnings related to known allergies to iodine or coexisting skin or thyroid conditions.

Q: If I miss a dose of my oral Co-op tablet, what should I do?

Official information for a missed dose during continuous administration typically states that the dose may be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the missed dose is generally skipped. It is specified that two doses should not be taken closer than the required 24 hour interval.

Q: Is the active ingredient in Co-op, Iodine, considered a controlled substance?

Iodine itself is not classified as a controlled substance like many pain medications. However, high-concentration forms of elemental Iodine (I2), such as powders, pellets, or strong solutions, are regulated by government agencies as a List I chemical. This means these specific chemical preparations are subject to tracking and specific handling regulations.

How should Co-op be stored and disposed of?

How to Store and Dispose of Co-op

The storage and disposal instructions for this medicine, which contains Codeine, are defined by official regulatory requirements to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, protected from excess heat.
Protection	Keep the product protected from moisture and direct light.
Packaging	Keep the medicine in its original container and ensure it is tightly closed.

Safety and Disposal

Due to the presence of an opioid, it is mandatory to keep this medicine out of the sight and reach of children and store it in a secure location. Unused or expired medication must not be disposed of in household trash or wastewater. The official requirement is to discard the product through a formal drug take-back program or as directed by local controlled substance regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Ireland

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z